NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides Phase II MPox Trial Approval in the Democratic Republic of Congo
TL;DR
NanoViricides' NV-387 Phase II approval positions the company as a leader in antiviral therapy with potential to dominate treatment for up to 95% of human pathogenic viruses.
NV-387 mimics human cells to trap and destroy viruses through nanoviricide technology, with Phase II trials now approved to assess safety and effectiveness against MPox.
This broad-spectrum antiviral could transform global health by providing effective treatment for multiple viral diseases, potentially reducing suffering from infections like COVID, influenza and MPox.
NanoViricides' virus-trapping nanotechnology represents a breakthrough approach that could revolutionize antiviral treatment similar to how antibiotics transformed bacterial disease management.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. has received regulatory approval from the Democratic Republic of Congo's ACOREP agency to begin a Phase II clinical trial evaluating NV-387 for the treatment of MPox caused by hMPXV infection.
This approval represents an important milestone in the regulatory development of NV-387 and moves the company closer to testing what they believe could be a major breakthrough in antiviral therapy, similar to how antibiotics transformed bacterial disease treatment.
NV-387 is designed to mimic human cells to trap and destroy viruses and has shown potential as a broad-spectrum antiviral targeting up to 95% of human pathogenic viruses.
The trial will be conducted in the Democratic Republic of Congo, where the regulatory approval was granted by ACOREP, the country's regulatory agency.
The trial is approved to begin pending final document submissions, and the company will assess both safety and effectiveness of NV-387 for MPox treatment.
The company plans to develop NV-387 as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, in addition to MPOX/Smallpox infections.
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy, licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
The company is developing drugs against oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, Ebola virus, and holds exclusive licenses for several other human viral diseases.
Anil R. Diwan, PhD, is the President and Executive Chairman of NanoViricides, Inc. and commented on the importance of this regulatory milestone.
More information is available at the company's website (www.nanoviricides.com) and the full press release can be viewed at https://ibn.fm/WdFf1.
Curated from InvestorBrandNetwork (IBN)
